Table 3. Trials for Oligometastatic Disease.

Year	Author	Protocol	Patients	Site	No. oflesions	LC	DC	PFS	OS	Reference
2007	Milano	50 Gy in 10 fx	121	Lung, Liver, Brain, Adrenal glands, Bone, Thoracic, pelvic, or abdominal lymph nodes	≤5	2-year 67%;4-year 60%	2-year 34%;4-year 34%	2-year 26%;4-year 20%	2-year 50%;4-year 28%	4
2008	Salama	24–60 Gy in 3–8 fx	29	Lung, Liver, Lymph nodes, Bone, Adrenal, Soft tissue	≤5	Median follow-up of 14.4 mo,79% without progressionin treated site	Median follow-upof 14.4 mo, 45%without distantdiseaseprogression	21% at median of14.4 months	NR	7
2009	Lee	Median dose 41.8 Gyin 6 fx	68	Liver	1–8	1-year 71%	NR	NR	17.6 monthsmediansurvival	3
2009	Rusthoven	Phase I 48–60 Gyin 3 fx; Phase II 60 Gyin 3 fx	38	Lung	1–3	1-year 100%;2-year 96%	NR	Distal progressionin 64% of pts(median4 months)	2-year 55% inpts w/o priorsystemic therapy;2-year 32% inpts with at leastone priorregimen	5
2009	Rusthoven	Phase I 36–60 Gyin 3 fx; Phase II 60 Gyin 3 fx	47	Liver	1–3	1-year 95%;2-year 92%	NR	Distal progressionin 83% of pts(median of 6 months)	2-year 30%	6
2011	Tong	Sunitinib 37.5 mg dailyfor 28 days; 50 Gyin 10 fx	25	Bone, Lung, Lymph nodes, Visceral	≤5	18-month 75%	18-month 52%	18-month56%	18-month 71%

Abbreviations: LC, local control; DC, distant control; PFS, progression-free survival; OS, overall survival; fx, fractions; NR = not reported.